Related Experiment Videos
Neuroleptic malignant syndrome in children
1Royal Children's Hospital, Parkville, VIC.
The Medical Journal of Australia
|September 16, 1991
Summary
Neuroleptic Malignant Syndrome (NMS) is rare in children but can be fatal. Early diagnosis and supportive care are crucial for recovery in pediatric NMS cases.
Area of Science:
- Pediatric Neurology
- Pharmacology
- Critical Care Medicine
Background:
- Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening condition.
- It is typically associated with antipsychotic medications, but can occur with other drugs.
- NMS is less common in children than in adults.
Observation:
- A case of NMS in a 6-year-old child treated with thioridazine for behavioral issues is presented.
- The child developed NMS following an episode of dehydration.
- Clinical features were compared to 11 other reported pediatric cases and adult NMS cases.
Findings:
- The pediatric patient recovered fully with supportive management.
- NMS in children, though rare, is often precipitated by commonly prescribed medications.
- Reported mortality rates for NMS in adults range from 15%-40%, with two of the 11 reviewed pediatric cases being fatal.
Implications:
- Early recognition and prompt treatment are vital for improving outcomes in pediatric NMS.
- Awareness of NMS is important for clinicians prescribing psychotropic medications to children.
- Further research into pediatric NMS, including treatment options like dantrolene and antiparkinsonian agents, is warranted.